Thoratec Corp.THOR recently announced the start of patient enrollment in the SHIELD II U.S. clinical trial, which aims at exploring the use of HeartMate PHP in patients undergoing high-risk ...

Richard Lord had congestive heart failure so advanced that he'd have shortness of breath from ­sitting on the couch or laying in bed. Doctors said his weakened heart would only keep him alive for ...

Thoratec Corp.THOR recently announced that its HeartMate PHP (Percutaneous Heart Pump) product has received the CE Mark approval. Subsequently, the company will be able to sell the product in the EU ...

PLEASANTON, Calif., /PRNewswire/ -- Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that its CE ...

PLEASANTON, Calif., May 3, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts ...

PLEASANTON, Calif., Thoratec Corporation, a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced the first ever HeartMate 3™ implant ...

Thoratec Corp. of Pleasanton warned consumers late Tuesday that four patients, including two who improperly used the company's popular heart pump device, had died. The users had experienced problems ...

, a world leader in device-based mechanical circulatory support (MCS) therapies to save, support, and restore failing hearts, announced today that it has successfully completed the first human use of ...

Thoratec Corp. on Wednesday won U.S. approval to sell an implantable heart device as a permanent treatment for patients too sick for transplants, opening a new market for the product. Thoratec already ...

Thoratec won FDA approval for a new external HeartMate II controller.--Courtesy of Thoratec Thoratec ($THOR) scored the FDA's blessing to market a next-generation ...

California's Thoratec ($THOR) grew revenue in its 2013 third quarter, thanks largely to the company's HeartMate pumps. But the product line's sales climb showed ...